Company profile: Nanospectra Biosciences
1.1 - Company Overview
Company description
- Provider of particle-based therapies for thermal destruction of solid tumors, including AuroLase Therapy using AuroShell nanoparticles that absorb near-infrared light to generate heat. Offers proprietary nanoshell technology with initial clinical trials demonstrating safety and efficacy. Licenses IP to Sebacia for laser-activated acne treatment and partners with LiteCure to treat solid tumors and surface lesions in animals.
Products and services
- Nanoshell Technology: Proprietary platform employing nanoparticles that convert light into heat, enabling selective thermal destruction of tumors without harming adjacent healthy tissue
- AuroLase Therapy: Near-infrared-activated therapy that ablates solid tumors using AuroShell nanoparticles, absorbing NIR light and converting it into localized heat to precisely destroy malignant tissue
- Clinical Trials for Solid Tumors: Initial-phase clinical program demonstrating safety and efficacy of Nanospectra’s technology for applications in solid tumors, tissue, and drug delivery
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nanospectra Biosciences
iOnctura
HQ: Switzerland
Website
- Description: Provider of clinical-stage biopharmaceutical therapies targeting immunosuppression in the tumor microenvironment to improve immune checkpoint therapies. Pipeline includes Roginolisib (IOA-244), a PI3Kδ inhibitor in Phase Ib/II for solid tumors and hematological malignancies; IOA-289, an autotaxin inhibitor in Phase Ib/II for pancreatic and other CAF-driven tumors; and preclinical IOA-359 (TGF-β) and IOA-237 (CD73 mAb).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full iOnctura company profile →
Calistoga Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutic oral medicines targeting selected isoforms of the PI3K pathway to improve the health of patients with cancer and inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Calistoga Pharmaceuticals company profile →
Allorion Therapeutics
HQ: United States
Website
- Description: Provider of small-molecule therapeutics for cancer and autoimmune diseases, including an EGFR L858R allosteric inhibitor program to enhance existing treatments and prevent resistance; ARTS-021, an oral CDK2 inhibitor in Phase I/II for advanced/metastatic solid tumors; ARTS-011, a selective TYK2 inhibitor in early development; and high-throughput phenotypic screening to identify Werner Helicase inhibitors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allorion Therapeutics company profile →
Allos Therapeutics
HQ: United States
Website
- Description: Provider of anti-cancer therapeutics, developing and commercializing treatments including FOLOTYN, a folate analogue metabolic inhibitor that accumulates in cancer cells to cause cell death. Also offers Causal AI to predict effects of clinical interventions for complex generics development, and Licensing & Pipeline co-development and drug licensing to make medications more accessible.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Allos Therapeutics company profile →
Delcath Systems
HQ: United States
Website
- Description: Provider of interventional oncology therapies for metastatic liver cancer, including HEPZATO KIT for adult patients with metastatic uveal melanoma using a hepatic delivery system; the CHEMOSAT Hepatic Delivery System for melphalan for percutaneous hepatic perfusion to treat liver cancers; and Percutaneous Hepatic Perfusion, a minimally invasive procedure delivering high-dose chemotherapy directly to the liver while isolating the organ from the body’s circulatory system.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Delcath Systems company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nanospectra Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nanospectra Biosciences
2.2 - Growth funds investing in similar companies to Nanospectra Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nanospectra Biosciences
4.2 - Public trading comparable groups for Nanospectra Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →